Risk for uveitis relapse after COVID-19 vaccination

作者全名："Zhong, Zhenyu; Wu, Qiuying; Lai, Yuxian; Dai, Lingyu; Gao, Yu; Liao, Weiting; Feng, Xiaojie; Yang, Peizeng"

作者地址："[Zhong, Zhenyu; Wu, Qiuying; Lai, Yuxian; Dai, Lingyu; Gao, Yu; Liao, Weiting; Feng, Xiaojie; Yang, Peizeng] Chongqing Med Univ, Affiliated Hosp 1, Chongqing Eye Inst, Chongqing Key Lab Ophthalmol, Chongqing, Peoples R China; [Zhong, Zhenyu; Wu, Qiuying; Lai, Yuxian; Dai, Lingyu; Gao, Yu; Liao, Weiting; Feng, Xiaojie; Yang, Peizeng] Natl Clin Res Ctr Ocular Dis, Chongqing Branch, Chongqing, Peoples R China; [Yang, Peizeng] Chongqing Med Univ, Affiliated Hosp 1, Youyi Rd 1, Chongqing 400016, Peoples R China"

通信作者："Yang, PZ (通讯作者)，Chongqing Med Univ, Affiliated Hosp 1, Youyi Rd 1, Chongqing 400016, Peoples R China."

来源：JOURNAL OF AUTOIMMUNITY

ESI学科分类：IMMUNOLOGY

WOS号：WOS:000868221600007

JCR分区：Q1

影响因子：12.8

年份：2022

卷号：133

期号：　

开始页：　

结束页：　

文献类型：Article

关键词：COVID-19; Vaccination; Uveitis relapse

摘要："Objectives: Several studies suggested that coronavirus disease 2019 (COVID-19) vaccination may lead to uveitis, a vision-threatening condition often associated with a variety of autoimmune or autoinflammatory diseases. This study aims to explore factors that influence the risk of uveitis relapse after COVID-19 vaccination to guide the prevention of disease.Methods: Uveitis relapse was evidenced by worsening activity of intraocular inflammation (e.g. anterior chamber cells, vitreous haze) as defined by the Standardization of Uveitis Nomenclature Working Group. Time to uveitis relapse since the administration of each dose of COVID-19 vaccine was compared across participants with modifiable variables.Results: The primary analysis included 438 non-COVID-19 participants with 857 doses of COVID-19 vaccine administered in total. The median age was 41 years (interquartile range, 30 to 51), and 57.3% were female. A total of 39 episodes of uveitis relapse events occurred in 34 patients after the receipt of a dose of COVID-19 vaccine within 30 days. The median time to relapse after vaccination was 5 days (interquartile range, 1 to 14). Concomitant use of systemic glucocorticoids at the time of vaccination was independently associated with a decrease in risk of relapse after vaccination (HR, 0.23 [95% CI, 0.07-0.74]; P value = 0.014). There was a trend in attenuating the risk of relapse with increasing prednisone dose from none to less than 20 mg per day and then to 20 mg per day or greater (P value for trend = 0.029).Conclusions: Concomitant treatment with systemic glucocorticoids for uveitis at the time of COVID-19 vaccination was associated with a dose-dependent lower risk of uveitis relapse after vaccination."

基金机构：National Natural Science Foundation of China Major International (Regional) Joint Research Project [81720108009]; Chongqing Outstanding Scientists Project (2019); Chongqing Chief Medical Scientist Project (2018); Chongqing Key Project [81720108009]; [CSTC2021jscx-gksb-N0010]

基金资助正文："The work was supported by National Natural Science Foundation of China Major International (Regional) Joint Research Project (81720108009) , Chongqing Key Project (CSTC2021jscx-gksb-N0010) , Chongqing Outstanding Scientists Project (2019) , and Chongqing Chief Medical Scientist Project (2018) ."